Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 85 Women only

Evaluating surgery with or without additional radiotherapy for intermediate risk cervical cancer

Official title: An International Randomised Trial of Radical Surgery Followed by Adjuvant (Chemo)Radiation Versus no Further Treatment in Patients With Early-stage, Intermediate-risk Cervical Cancer Patients

Run by The Central and Eastern European Gynecologic Oncology Group · NCT04989647 · Data updated 2026-11-12

This study is testing if adding radiation therapy after surgery helps people with intermediate risk cervical cancer live longer without their cancer coming back.

More Cervical Cancer trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 85 Years
SexWomen only
Enrollment514 (estimated)
SponsorThe Central and Eastern European Gynecologic Oncology Group
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Prague)
StatusRecruiting
StartedJune 10, 2022
Main results expectedDecember 2029
Study endsDecember 2032
Registry record updatedSeptember 7, 2023
Trial IDNCT04989647 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with pathologically confirmed invasive cervical cancer classified as FIGO IB1-IIA and exhibiting specific tumor-related risk factors.

Probably not a fit

Patients with adenosquamous cancer or unusual types of adenocarcinoma, as well as those with evidence of lymph node involvement or distant metastases, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to determine whether adjuvant (chemo)radiotherapy improves disease-free survival in patients with intermediate risk cervical cancer after radical surgery. A total of 514 patients will be enrolled and randomly assigned to receive either no additional treatment or adjuvant radiotherapy following surgery. The study will assess the primary endpoint of disease-free survival using a Cox proportional hazards model, with a focus on providing high-quality evidence regarding the effectiveness of adjuvant treatment in this patient population.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the role of adjuvant therapy, potentially improving outcomes for patients with intermediate risk cervical cancer.

How similar studies have gone: Previous studies have shown mixed results regarding the role of adjuvant treatment in similar patient populations, making this trial a significant effort to clarify the issue.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pathologically confirmed invasive cervical cancer
* FIGO IB1-IIA
* Squamous cell cancer or HPV-related adenocarcinoma
* Presence of tumour-related risk factors as follows:

  1. tumour ≥4 cm OR
  2. tumour\>2 cm \<4 cm AND lymphovascular space invasion OR
  3. tumour \>2 cm \<4 cm AND tumour free distance \<3 mm OR
  4. tumour \>2 cm \<4 cm AND deep stromal invasion (\>2/3)
* No evidence of suspicious pelvic lymph nodes or distant metastases on imaging (by radiological subjective assessment before surgery and negative pelvic LN on final pathology)
* ECOG performance status 0-1
* Deemed suitable and fit for radical surgery followed by adjuvant radiotherapy
* Negative pregnancy test (if applicable)
* Negative HIV test (only performed in high-risk countries or patients who have moved from those countries within the past 10 years)

Exclusion Criteria:

* Adenosquamous cancer or adenocarcinoma unusual type (non-HPV related - such as: mucinous, clear cell, mesonephric) or other rare tumour types (those not listed in the inclusion criteria)
* Inconclusive primary site of disease
* Unequivocally positive lymph node by imaging (by radiological subjective assessment)
* FIGO \<IB1 / \>IIA
* Previous pelvic malignancy
* History of second primary cancer outside pelvis if ≤ 3 years complete clinical remission (CCR)
* Previous pelvic radiotherapy
* Neoadjuvant chemotherapy prior surgical treatment
* Low likelihood of patient compliance to the follow-up

Where it's running

  • General University Hospital in Prague
    Prague, Czechia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.